DRTS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

7.120

Open

6.750

VWAP

6.95

Vol

114.24K

Mkt Cap

609.03M

Low

6.740

Amount

794.36K

EV/EBITDA(TTM)

--

Total Shares

88.01M

EV

542.25M

EV/OCF(TTM)

--

P/S(TTM)

--

Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.

Show More

Events Timeline

(ET)

2026-02-24

09:10:00

Alpha Tau Medical Receives Japan Approval for Alpha DaRT in Head and Neck Cancer

2026-01-29 (ET)

2026-01-29

09:20:00

Alpha Tau Medical Updates on Clinical Trial Progress

2026-01-06 (ET)

2026-01-06

09:30:00

Alpha Tau Medical Releases Final Results from Pancreatic Cancer Study

2026-01-05 (ET)

2026-01-05

09:10:00

Alpha Tau Medical Submits Pre-Market Approval Application for Alpha DaRT to FDA

2025-12-09 (ET)

2025-12-09

09:10:00

Alpha Tau Medical Treats First Patient with Alpha DaRT for Recurrent Glioblastoma

News

Newsfilter

03-31Newsfilter

Alpha Tau Medical to Present Clinical Trial Results at DDW 2026

stocktwits

03-30stocktwits

Alpha Tau Medical Advances Clinical Trials for Cancer Treatments

seekingalpha

03-09seekingalpha

Alpha Tau Medical Reports FY GAAP EPS of -$0.42

Yahoo Finance

02-25Yahoo Finance

Japan Approves New Head and Neck Cancer Treatment Device

NASDAQ.COM

01-23NASDAQ.COM

Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading

Benzinga

TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%

3 Analyst Rating

Wall Street analysts forecast DRTS stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

7.00

High

9.00

Current: 0.000

Low

5.00

Averages

7.00

High

9.00

Citi

Yigal Nochomovitz

Buy

maintain

$7 -> $9

AI Analysis

2026-03-11

Reason

Citi

Yigal Nochomovitz

Price Target

$7 -> $9

AI Analysis

2026-03-11

maintain

Buy

Reason

Citi analyst Yigal Nochomovitz raised the firm's price target on Alpha Tau to $9 from $7 and keeps a Buy rating on the shares. The firm believes the company's radiopharma platform is being underappreciated at current share levels. Alpha Tau's "broader-than-expected" Japan approval in head and neck cancer is leading to partnership opportunities, the analyst tells investors in a research note.

Piper Sandler

Jason Bednar

Overweight -> Neutral

downgrade

$5

2026-03-04

Reason

Piper Sandler

Jason Bednar

Price Target

$5

2026-03-04

downgrade

Overweight -> Neutral

Reason

Piper Sandler analyst Jason Bednar downgraded Alpha Tau to Neutral from Overweight with an unchanged price target of $5. The firm cites valuation for the downgrade. The stock rallied after a "handful of minor fundamental positives," the analyst tells investors in a research note. Piper believes the next leg higher for the stock will require real revenue realization to be a near-term event. However, Alpha 's path to full commercialization of its DaRT technology is still at least 2-3 years away, contends the firm.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DRTS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Alpha Tau Medical Ltd (DRTS.O) is 0.00, compared to its 5-year average forward P/E of -12.64. For a more detailed relative valuation and DCF analysis to assess Alpha Tau Medical Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-12.64

Current PE

0.00

Overvalued PE

-1.36

Undervalued PE

-23.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-4.63

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.24

Undervalued EV/EBITDA

-9.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

392.76

Current PS

37.67

Overvalued PS

1107.04

Undervalued PS

-321.51

Financials

AI Analysis

Annual

Quarterly

Whales Holding DRTS

Trading Trends

People Also Watch

Frequently Asked Questions

What is Alpha Tau Medical Ltd (DRTS) stock price today?

The current price of DRTS is 7 USD — it has increased 1.16

What is Alpha Tau Medical Ltd (DRTS)'s business?

Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.

What is the price predicton of DRTS Stock?

Wall Street analysts forecast DRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Alpha Tau Medical Ltd (DRTS)'s revenue for the last quarter?

Alpha Tau Medical Ltd revenue for the last quarter amounts to -12.60M USD, increased 22.66

What is Alpha Tau Medical Ltd (DRTS)'s earnings per share (EPS) for the last quarter?

Alpha Tau Medical Ltd. EPS for the last quarter amounts to -9120000.00 USD, increased 221.47

How many employees does Alpha Tau Medical Ltd (DRTS). have?

Alpha Tau Medical Ltd (DRTS) has 121 emplpoyees as of April 03 2026.

What is Alpha Tau Medical Ltd (DRTS) market cap?

Today DRTS has the market capitalization of 609.03M USD.